Successful use of cemiplimab in a high immunologic risk kidney transplant recipient with metastatic squamous cell carcinoma
Transplant Immunology · 2025
DOI: 10.1016/j.trim.2025.102242 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transplant Immunology, 2025. Verfasst von Elena-Bianca Barbir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Hypertension and Transplantation, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Squamous Cell, Graft Rejection, Immune Checkpoint Inhibitors. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb Foundation.
Abstract (Originalsprache)
The widespread use of immunotherapy in the management of cancers has led to improved overall survival and progression free survival. Due to increased risk of allograft rejection, organ transplant recipients are often excluded in clinical trials or offered immunotherapy only as salvage therapy. We report a case of successful use of Cemiplimab, an immune checkpoint inhibitor, in a high immunologic risk kidney transplant recipient who was diagnosed with metastatic squamous cell carcinoma (SCC) twenty-five months post-transplant. He started Cemiplimab five months post diagnosis of SCC, as third line therapy, after demonstrating progression of metastatic skull-based disease on prior lines of therapy. His maintenance immunosuppression was changed from triple immunosuppression with tacrolimus, mycophenolate and prednisone to sirolimus with a high trough target of 10-15 ng/mL and steroid therapy. He tolerated the high sirolimus trough and continued on Cemiplimab for six months with clinically stable allograft function and a good quality of life. Notably, he demonstrated response of his previously chemotherapy refractory metastatic disease. He passed away from radiation necrosis of the brain at sixty-eight months post-transplant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Hypertension and Transplantation, University of Alberta, Edmonton, AB, Canada.
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States of America.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America.
- Division of Oncology, Mayo Clinic, Rochester, MN, United States of America.
- Department of Kidney Medicine, Medical Specialties Institute Cleveland Clinic, Cleveland, OH, United States of America. Electronic address: owoyemi@ccf.org.
Förderung
- Bristol-Myers Squibb Foundation
Zitieren
APA
Barbir, E. B., Jalal, A., Grande, J., Markovic, S. N., Kukla, A., & Owoyemi, I. (2025). Successful use of cemiplimab in a high immunologic risk kidney transplant recipient with metastatic squamous cell carcinoma. Transplant Immunology. https://doi.org/10.1016/j.trim.2025.102242
Vancouver
Barbir EB, Jalal A, Grande J, Markovic SN, Kukla A, Owoyemi I. Successful use of cemiplimab in a high immunologic risk kidney transplant recipient with metastatic squamous cell carcinoma. Transplant Immunology. 2025. doi:10.1016/j.trim.2025.102242
BibTeX
@article{Barbir2025,
author = {Barbir, Elena-Bianca and Jalal, Abdullah and Grande, Joseph and Markovic, Svetomir N and Kukla, Aleksandra and Owoyemi, Itunu},
title = {Successful use of cemiplimab in a high immunologic risk kidney transplant recipient with metastatic squamous cell carcinoma},
journal = {Transplant Immunology},
year = {2025},
doi = {10.1016/j.trim.2025.102242}
}
EUVIMED